Anixa Biosciences (NASDAQ:ANIX), Inc. (NASDAQ:ANIX) is a clinical-stage biotechnology company focused on developing immunotherapies and diagnostic solutions for oncology. Headquartered in San Jose, California, Anixa leverages proprietary vaccine and cell therapy platforms to target solid tumors, with an initial emphasis on ovarian cancer. The company’s mission centers on harnessing the body’s immune response to improve patient outcomes across a range of malignancies.
The company’s immuno-oncology pipeline features a multi-antigen cancer vaccine designed to stimulate both innate and adaptive immunity against tumor cells. In pre-clinical and early clinical studies, Anixa’s lead therapeutic candidates have demonstrated the potential to generate robust T-cell responses against key tumor-associated antigens. In addition to its vaccine programs, Anixa is advancing adoptive cell therapies that combine personalized T-cell expansion techniques with its proprietary antigen targets.
Beyond therapeutics, Anixa Biosciences has developed a suite of diagnostic assays aimed at the early detection of ovarian and other gynecologic cancers. Utilizing a proprietary biomarker panel, the company’s diagnostic tests are designed to identify disease at an earlier stage than traditional imaging or symptom-based approaches. Anixa collaborates with academic research centers and diagnostic laboratories across North America and Europe to validate and commercialize these assays.
Founded in 2015, Anixa is led by CEO Bill Burns, a veteran of biotech venture capital and corporate development, alongside a management team with extensive experience in immunology, translational research, and regulatory affairs. The company continues to expand its scientific advisory board and R&D capabilities, positioning itself at the forefront of next-generation cancer immunotherapies and precision diagnostics.
